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Survey database. The study population included individuals above 18 years of age, 
suffering from depression (ICD-9-CM: 296, 300, and 311). HRQOL was assessed 
using SF-12 physical component summary (PCS) and mental component sum-
mary (MCS) scores. The significant predictors of HRQOL were identified using a 
multiple logistic regression model. SAS version 9.1 (SAS institute, Cary, NC) was 
used for data analysis. RESULTS: 2971 individuals were identified with depression. 
Impairments in both the domains of HRQOL were found. Young adults (OR= 0.198, 
95%CI = 0.116-0.337) were significantly less likely of showing lower PCS scores as 
compared to older adults. Unemployed (OR= 2.5, 95%CI= 1.981-3.182), less edu-
cated (OR= 1.49, 95%CI = 1.20-1.84) and individuals reporting poor perceived health 
(OR= 1.62, 95%CI = 1.43-12.99) had significantly higher odds of showing lower PCS 
scores compared to employed, more educated individuals having a better perceived 
health . Furthermore, middle aged adults (OR= 2.41, 95%CI = 1.78-3.28), unemployed 
(OR= 1.38, 95%CI = 1.08-1.76),less educated(OR= 1.31, 95%CI = 1.07-1.62) and indi-
viduals showing poor mental health (OR= 3.1,95%CI= 2.27-4.24) and overall per-
ceived health (OR= 1.72,95%CI= 1.32-2.25)showed significantly lower MCS scores. 
This was observed in comparison to older, employed, more educated individuals 
reporting good overall health and mental health status. CONCLUSIONS: Socio-
demographically disadvantaged people and people reporting lower perceived health 
status are at greater risk of having a poor quality of life. The factors identified in 
this study should be further investigated to evaluate why such differences exist in 
quality of life of depressed individuals.
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OBJECTIVES: Eating disorders are psychological conditions characterized by dis-
turbed eating habits affecting approximately 30% of teen girls with significant 
effects on their health related quality of life (HRQL). The objective of this study 
was to compare and contrast psychometric properties of eating disorder specific 
HRQL instruments. METHODS: HRQL instruments were included in this review 
if they were available in English, and there was at least one publication citing 
psychometric properties. Study instruments were evaluated based on: conceptual 
model, versatility (type of disorder), practicality, depth (< 15%), reliability (internal 
consistency and test-retest), construct validity (convergent and divergent or con-
firmatory factor analysis), and responsiveness. RESULTS: Six instruments were 
identified: Eating disorder quality of life (EDQOL), eating disorder quality of life 
scale (EDQLS), health related quality of life in eating disorder and its abbrevi-
ated version (HeRQoLED v2), Quality of life for eating disorders (QOL ED), and 
eating disorder well-being scale (EDwell). All instruments were developed for 
self-administration, taking 5-15minutes to complete, designed for use in female 
teens/adults supported by construct validity data, with most scales supporting 
group- as opposed to individual- level decision making. Only HeRQoLEDv2 was 
developed for use in both genders. Lack of meeting study criteria may be attrib-
uted to missing data, e.g., test-retest reliability. None of the six instruments met 
all study criteria; however, EDQLS and HeRQoLEDv2 met almost all study cri-
teria. CONCLUSIONS: All eating disorder instruments reviewed were developed 
within the last 10 years with available data being inadequate to assess all scales. 
Similar to Tirico et al. (2000), in the present study EDQLS and HeRQoLEDv2 met 
most of the study criteria, in contrast, EDQOL was excluded from this list due to 
missing data, Study data supported individual level decision making only for the 
HeRQoLEDv2.
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OBJECTIVES: Few studies have measured the impact of antidepressant treatment 
on family functioning. The effect of vortioxetine and agomelatine on different 
domains of family functioning was measured using the Depression and Family 
Functioning Scale (DFFS), comprising 15 items, each rated from 0-4. METHODS: 
The DFFS was assessed in REVIVE, a randomized, double-blind study of adults 
with an inadequate response to antidepressant treatment for the current depres-
sive episode switched to vortioxetine or agomelatine (NCT01488071). Pre-specified 
analyses of patients with baseline and follow-up DFFS assessments were per-
formed using change from baseline to weeks 8 and 12, analyzed by mixed models 
for repeated measurements (MMRM). Descriptive statistics characterizing depres-
sive symptoms (Montgomery-Åsberg Depression Rating Scale; MADRS), function-
ing (Sheehan Disability Scale; SDS), and quality of life (QoL; EQ-5D) were stratified 
according to DFFS total score quartiles at baseline. RESULTS: The DFFS total score 
was ~29 at baseline. Vortioxetine (n= 189) was superior to agomelatine (n= 187) by 
2.9 (95% CI [-4.7 to -1.1]) points at week 8 (p< 0.01) and at week 12 by 2.5 (95% CI 
[-4.5 to -0.5; p< 0.05]) points. Improvements in the DFFS total score and items were 
observed from baseline to week 8 (-10.8±0.7 (vortioxetine) and -7.9±0.7 (agomela-
tine), with further improvement at week 12 (-13.5±0.8 (vortioxetine) and -11.0±0.8 
(agomelatine)). At baseline, the level of family functioning was associated with 
functional and QoL impairment and, to a lesser extent, depressive symptoms 
(SDS total= 14.66, 19.31, 20.25, 21.68; EQ-5D= 0.68, 0.58, 0.53, 0.44; MADRS= 26.97, 
28.83, 29.39, 29.67 in the first, second, third, and fourth DFFS quartiles, respec-
tively; p< 0.01). CONCLUSIONS: Vortioxetine was significantly superior to ago-
melatine in terms of change in DFFS total score at weeks 8 and 12. Depressed 
patients with impaired family functioning showed worse overall functioning and 
QoL, suggesting that attention should be given to family functioning of depressed 
patients.
PMH53
antiPsycHotics treatMent and Quality of life in scHizoPHrenia 
Patients
Sriramula S.1, Yerra S.1, Veerareddy P.R.2
1SS Hospital, Warangal, India, 2College of Pharmacy, Mahabubnagar, India
OBJECTIVES: A study was done at tertiary care hospital to find the clinical evalu-
ations with particular identification and quality of life in schizophrenia patients. 
Patients visiting the psychiatry clinic were screened for psychological problems 
using a standard questionnaire and patients with history of psychiatry problems 
over a period of years. METHODS: It was a possible observational study for 6 
months in a hospital. The study enrolled 150 in-patients and out-patients with 
Schizophrenia. Patients were included in the study who met addition criteria 
after obtaining their knowledgeable permission. Patient history, principal symp-
toms, physical examination and computed tomography scan information were 
taken as the pretreatment evaluation. Antipsychotic drugs (Chlorpromazine and 
Haloperidol) were used in the patients to find the clinical evaluations and qual-
ity of life was analyzed. RESULTS: A study was conducted to search the clini-
cal profile, patient behavioural symptoms of drugs used among schizophrenia 
patients. A major number of patients who visited the hospital were diagnosed 
with different psychotic disorders. Among patients who were diagnosed with 
schizophrenia, 52% were males and 48% were females. Major factors were found 
to be family history (43%), alcohol (15%), thyroid disorders (7%), family problems 
(7%), and post menopausal problems (1%). Symptoms shown by the patients were 
abnormal behaviour (75%), smiling to self (15%), talking to self (29%), hallucinations 
(39%), aggressive (25%), sleeplessness (42%). Most common people affected were 
between 20-25 age groups (23%). CONCLUSIONS: It was concluded that patients 
were better recovered through treatment using Chlorpromazine and Haloperidol. 
Electro convulsive therapy through supportive treatment was used to improve the 
quality of life of the patients.
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OBJECTIVES: Measure the impact of reduced copay intervention on medication usage, 
healthcare utilization and costs, and health status. METHODS: A self-insured global 
healthcare company followed 529 insured members with anxiety and/or depression 
to determine the impact of waived pharmacy copays for anxiety and depression 
medications. Primary outcome was pre-post change in medication possession ratio 
(MPR). Secondary outcomes included initiation of medication, healthcare utilization, 
medical/pharmacy costs, and percentage of generic medication. A repeated-measures 
multivariable model was utilized to measure intervention impact, adjusting for age, 
gender, number of prescriptions, and comorbidity index. RESULTS: Unadjusted analy-
sis showed the copay intervention group was significantly more likely to start a new 
medication (31.4% vs. 29.5%, p = 0.033) and more likely to fill a generic medication 
(85.1% vs. 80.5%, p < 0.0001), and had higher average MPR (65.4% vs. 60.7%, p = 0.004) 
than the control group. Healthcare utilization was similar pre-post intervention. 
Multivariable adjusted analysis revealed a 4.5% increase in MPR after the interven-
tion (95% CI 2.2% - 6.8%, p = 0.0002). CONCLUSIONS: Eliminating pharmacy copay 
for depression and/or anxiety medications was associated with increased medica-
tion initiation and adherence. This value-based benefit design could be expanded 
with additional follow-up to measure longer-term trends and with other medication 
classes to assess similar impact.
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OBJECTIVES: This metareview identifies the common elements associated with 
published behavioral health-physical health (BH-PH) collaboration/integration 
strategies for managing comorbid conditions. METHODS: PubMed, Cochrane 
Library, and the Academy (AHRQ) were searched using keywords “review” or “meta-
analysis” and any combination of: “collaboration,” “integrated,” “behavioral,” “men-
tal,” “primary care,” “general practice,” “depression,” “schizophrenia,” “bipolar,” 
“panic,” anxiety,” “alcohol,” and “substance abuse.” RESULTS: The search identi-
fied 110 systematic reviews and/or meta-analyses covering BH-PH collaboration/
integration strategies, referencing almost 3,000 studies. Most studies addressed 
integration of BH services into primary care (PC), primarily major depression (less 
frequently anxiety, somatization, alcohol and addiction disorders) in adults and/or 
elderly. Some described integration of BH services into outpatient and community 
settings—effective venues for strategies like diet and exercise—or PH services 
in BH settings. Provider integration strategies usually included a psychiatrist or 
clinical psychologist available for PC consultation, but also therapists, BH-trained 
clinical nurses, social workers, care managers, and/or community health workers. 
Integrated BH-PH care models achieved clinically meaningful improvements in 
depression- and anxiety-related primary and secondary outcomes. Recent indi-
vidual studies have also reported improvements in medical/clinical outcomes 
(e.g., HbA1c in TEAMcare study) and physical functioning. The extent of integra-
tion was not significantly associated with depression or anxiety outcomes. No 
best practices (e.g., colocation) have been definitively validated as significant 
predictors for promoting positive health outcomes; rather, successful strategies 
implement multifaceted, system-level interventions, including brief psychologi-
